Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lymphoid Cells and Tissues

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026

Same author

Rethinking Cardiovascular Events, End Points, and Surveillance in Oncology Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Kidney Involvement in Sarcoidosis-Lymphoma Syndrome: A Report of Two Cases.

CEN case reports·2026

Same author

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Cancers·2026

Same author

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Cancers·2026

Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 13, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Non-Hodgkin's lymphomas, version 1.2013.

Andrew D Zelenetz¹, William G Wierda, Jeremy S Abramson

¹Memorial Sloan-Kettering Cancer Center, USA.

Journal of the National Comprehensive Cancer Network : JNCCN

|March 15, 2013

Summary

This summary is machine-generated.

NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) have been updated. New recommendations cover chronic lymphocytic leukemia treatments and managing hepatitis virus infections in high-risk NHL patients undergoing therapy.

More Related Videos

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Related Experiment Videos

Last Updated: May 13, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Area of Science:

Oncology
Hematology
Clinical Guidelines

Background:

Non-Hodgkin's Lymphomas (NHL) encompass a diverse group of lymphoid malignancies.
Treatment decisions for NHL require consideration of specific subtypes and patient risk factors.
Managing complications like viral reactivation is crucial during antitumor therapy.

Purpose of the Study:

To summarize key updates to the NCCN Guidelines for NHL.
To provide clinical evidence supporting recent guideline revisions.
To offer guidance on specific treatment and management challenges in NHL.

Main Methods:

Review of NCCN Guidelines for Non-Hodgkin's Lymphomas.
Analysis of clinical evidence supporting guideline changes.
Synthesis of recommendations for chronic lymphocytic leukemia and hepatitis virus management.

Main Results:

Updated recommendations for additional treatment options in chronic lymphocytic leukemia.
Guidance on managing hepatitis virus reactivation/infections in high-risk NHL patients.
Evidence-based support for the discussed guideline updates.

Conclusions:

The updated NCCN Guidelines offer enhanced treatment strategies for NHL patients.
Proactive management of hepatitis virus is essential for patients undergoing NHL therapy.
These insights aim to improve clinical decision-making in NHL care.